- ►diabetesjournals.org K Krzyzanowska, F Mittermayer, M Wolzt, G … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS— During a median follow-up of 21 (interquartile range 11–27) months,
84 events occurred in 48 patients. According to multivariate Cox regression
analysis, patients with baseline ADMA or CRP in the highest tertile had a ... Cited by 30 - Related articles - BL Direct - All 6 versions
- Free from Publisher M Lajer, L Tarnow, A Jorsal, T Teerlink, HH … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We performed a prospective observational follow-up
study including 397 type 1 diabetic patients with overt diabetic nephropathy
(243 men aged 42.1 ± 10.5 years, GFR 76 ± 34 ml/min per 1.73 m 2 ) and a ... Cited by 16 - Related articles - BL Direct - All 4 versions
- ►ahajournals.org C Duckelmann, F Mittermayer, DG Haider, J … - Arteriosclerosis, Thrombosis, and Vascular Biology, 2007 - Am Heart Assoc Methods and Results— 253 patients with symptomatic chronic HF and impaired
left ventricular function (median age 70 years, 202 males) were followed for a
median of 14.2 months (interquartile range 6.8 to 21.2). ADMA and ... Cited by 18 - Related articles - All 8 versions
- ►ahajournals.org F Mittermayer, K Krzyzanowska, M Exner, W … - Arteriosclerosis, thrombosis, and vascular biology, 2006 - Am Heart Assoc Methods and Results— We prospectively enrolled 496 of 533 consecutive patients
with PAD (median age 70 years, 279 males). ADMA and L-arginine were assessed at
baseline by high performance liquid chromatography. The occurrence of MACE ( ... Cited by 46 - Related articles - All 9 versions
- ►ahajournals.org F Scalera, J Martens-Lobenhoffer, A … - Hypertension, 2008 - Am Heart Assoc Telmisartan, in addition to blocking angiotensin (Ang) II type 1 receptor (AT 1
R), activates peroxisome proliferator activated receptor (PPAR ) signaling that
interferes with nitric oxide (NO) system. Because aging of endothelial ... Cited by 10 - Related articles - All 5 versions
K Krzyzanowska, F Mittermayer, W Krugluger, … - Atherosclerosis, 2006 - Elsevier The endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine
(ADMA) and total homocysteine (tHcy) are elevated in patients at increased
cardiovascular risk. Patients with type 2 diabetes (T2DM) have higher ... Cited by 22 - Related articles - All 12 versions
K Krzyzanowska, F Mittermayer, C Schnack, M … - European journal of clinical investigation, 2005 - pt.wkhealth.com Results: Asymmetrical dimethylarginine was significantly higher in the
hypopituitary patients than in the controls (0·63 ± 0·12 vs. 0·51 ± 0·15
μmol L -1 ; P < 0·005). L-arginine and the L-arginine/ADMA ratios were ... Cited by 9 - Related articles - All 7 versions
- ►diabetesjournals.org MT Malecki, A Undas, K Cyganek, B … - Diabetes Care, 2007 - Am Diabetes Assoc Decreased availability of nitric oxide (NO), which contributes to the
development of diabetes vascular complications (1), is partially related to
asymmetric dimethylarginine (ADMA). ADMA is an endogenous NO synthase ... Cited by 8 - Related articles - BL Direct - All 4 versions
- ►ahajournals.org [PDF] M Zeller, C Korandji, JC Guilland, P Sicard, C … - Arteriosclerosis, Thrombosis, and Vascular Biology, 2008 - Am Heart Assoc Objective—Asymmetrical dimethylarginine (ADMA) is an endogenous competitive
inhibitor of nitric oxide (NO) synthases. From a prospective cohort of patients
with acute myocardial infarction (MI), we aimed to analyze the predictive ... Cited by 9 - Related articles - All 8 versions
- ►ahajournals.org [PDF] T Leong, D Zylberstein, I Graham, L Lissner, … - Arteriosclerosis, Thrombosis, and Vascular Biology, 2008 - Am Heart Assoc Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone:
410-528-4050. Permissions: Permissions & Rights Desk, Lippincott Williams &
Wilkins, a division of Wolters ... 24-Year Follow-Up of the Population ... Cited by 15 - Related articles - All 8 versions
